CANF 6-K: SEC filing
Can-Fite BioPharma
Filed with the SEC on · accession 0001213900-26-117184
CANF filed a 6-K (foreign company report) with the SEC on Nov 9, 2026. Can-Fite BioPharma announced a ten-year survival milestone for an advanced liver cancer patient treated in its Phase II Namodenoson study.
Summary of the filing
Can-Fite BioPharma announced a ten-year survival milestone for an advanced liver cancer patient treated in its Phase II Namodenoson study. The company issued a press release on November 9, 2026, highlighting the long-term survival outcome.
Key details
✦ Ask GOAX AI about this filing — what it means for CANF, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for CANF?
Click hereFrequently asked questions
What did CANF file with the SEC on Nov 9, 2026?
CANF filed a 6-K (SEC filing). Can-Fite BioPharma announced a ten-year survival milestone for an advanced liver cancer patient treated in its Phase II Namodenoson study. The company issued a press release on November 9, 2026, highlighting the long-term survival outcome.
How do I read a 6-K?
How foreign companies listed in the US report news and events — like an 8-K for them. Look at the exhibit names: "results", "resign", "notice" tell you the topic. Many 6-Ks are routine (meeting notices); results and leadership changes matter most.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 6-K (foreign company report): How foreign companies listed in the US report news and events — like an 8-K for them.
Other CANF SEC filings
Get alerts when CANF files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days